CUMYL-CBMICA

CUMYL-CBMICA is a synthetic cannabinoid of the indole-3-carboxamide family, first identified in July 2019 by the European project ADEBAR plus. It acts on the CB1 receptor as a full agonist, with a Ki of 29.3 nM in competitive binding (Haschimi et al., 2021), a lower affinity than that of its indazole analogue, CUMYL-CBMINACA, whose Ki is 1.32 nM. It is at once the most widespread of the six SCRAs compared by Pulver et al. (2023) and the least active of them. Human data remain limited to forensic medicine observations, and the sources consulted contain neither a pharmacokinetic study nor a controlled toxicological study.

Source

Entirely synthetic molecule, absent from cannabis and from any other plant. It was found in herbal products (Halter et al., 2021), distributed through online shops (Haschimi et al., 2021), within the market for synthetic cannabinoids known as "spice" (Groth et al., 2023). It belongs to the cyclobutylmethyl (CBM) subclass of SCRAs, whose members emerged between 2019 and 2021 (Pulver et al., 2023).

No biosynthetic pathway: this molecule is produced by no living organism and comes solely from chemical synthesis. It results from an organic synthesis of the amide type, described here by chemical class only.

European Union

No harmonised control measure at Union level is documented in the sources consulted, so control remains national. The molecule was the subject of a formal notification to the European early warning system of the EMCDDA (now EUDA) after its identification in 2019 (Halter et al., 2021). In Germany, the 2020 reform of the new psychoactive substances act placed all SCRAs with a cyclobutylmethyl side chain under control (Pulver et al., 2023).

France

This molecule is not named in the consolidated list of narcotics published by ANSM, updated on 16 February 2026. It does, however, fall within the generic clause for "3-carboxamide indole derivatives" in annex IV of the order of 22 February 1990. Each condition of that definition is met: the indole nitrogen carries a cycloalkylmethyl group (cyclobutylmethyl), the carboxamide bridge carries a cumyl-type substituent, and the indole ring may or may not be further substituted. It is therefore classed as a narcotic through the generic clause. Production, possession, transfer and use fall under the criminal regime for narcotics.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

1. 1Halter et coll., identification et caractérisation du Cumyl-CBMICA, Drug Testing and Analysis, 2021 (new tab)PMID 33037749
2. 2Haschimi et coll., métabolisme de phase I humain et affinité CB1 du Cumyl-CBMICA et du Cumyl-CBMINACA, Drug Testing and Analysis, 2021 (new tab)PMID 33788409
3. 3Cannaert et coll., activation de CB1 in vitro par des SCRA récents dont le Cumyl-CBMICA, ACS Chemical Neuroscience, 2020 (new tab)PMID 33253529
4. 4Janssens et coll., bibliothèque systématique de SCRA cumyle à chaînes alkyles et alicycliques, ACS Chemical Neuroscience, 2023 (new tab)PMID 36530139
5. 5Pulver et coll., pharmacologie et prévalence en Allemagne des SCRA à chaîne cyclobutylméthyle et norbornylméthyle, Drug Testing and Analysis, 2023 (new tab)PMID 36541839
6. 6Groth et coll., décès liés au « spice » autour de Munich de 2014 à 2020, International Journal of Legal Medicine, 2023 (new tab)PMID 37072496
7. 7Gampfer et coll., cytotoxicité de NPS sur cellules HepG2 par criblage à haut contenu, Toxicology, 2022 (new tab)PMID 35842060
8. 8ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, dérivés du 3-carboxamide indole) (new tab)
9. 9INCB, Green List 2026 (substances des tableaux de la Convention de 1971) (new tab)
10. 10PubChem, Cumyl-CBMICA, CID 155884426 (new tab)

SMILES

CC(C)(NC(=O)C1=CN(CC2CCC2)C2C=CC=CC=21)C1C=CC=CC=1

InChIKey

INXXQNIOWMOYEJ-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.